Pro32Pro33 mutations in the integrin β3 PSI domain result in αIIbβ3 priming and enhanced adhesion: Reversal of the hypercoagulability phenotype by the Src inhibitor SKI-606

Molecular Pharmacology

Volumn 85, Issue 6, 2014, Pages 921-931

  Oliver, Kendra H ^a   Jessen, Tammy ^a   Crawford, Emily L ^a   Chung, Chang Y ^a   Sutcliffe, James S ^a   Carneiro, Ana M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; BOSUTINIB; FIBRINOGEN; FIBRINOGEN RECEPTOR; PROLINE; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR 4; TALIN; THROMBIN RECEPTOR; ANILINE DERIVATIVE; NITRILE; PRIMER DNA; QUINOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CARDIOVASCULAR RISK; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOPLASM; ENZYME PHOSPHORYLATION; HEMOSTASIS; HYPERCOAGULABILITY; IN VIVO STUDY; LIGAND BINDING; MOUSE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; RISK REDUCTION; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS; AMINO ACID SEQUENCE; ANIMAL; CELL ADHESION; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SEQUENCE HOMOLOGY; THROMBOPHILIA;

AMINO ACID SEQUENCE; ANILINE COMPOUNDS; ANIMALS; BASE SEQUENCE; CELL ADHESION; DNA PRIMERS; HUMANS; INTEGRIN BETA3; MICE; MOLECULAR SEQUENCE DATA; MUTATION; NITRILES; PHENOTYPE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POLYMERASE CHAIN REACTION; PROLINE; QUINOLINES; SEQUENCE HOMOLOGY, AMINO ACID; SRC-FAMILY KINASES; THROMBOPHILIA;

EID: 84902984833     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.091736     Document Type: Article

References (62)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Sabaté M, Fernández C, Stranieri C, Trabetti E, Pignatti PF, and Macaya C (2004) PlA polymorphism and platelet reactivity following clopidogrel loading dose in patients undergoing coronary stent implantation. Blood Coagul Fibrinolysis 15:89-93.
2. Arias-Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH, and Shattil SJ (2003) Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc Natl Acad Sci USA 100:13298-13302.
3. Arias-Salgado EG, Lizano S, Shattil SJ, and Ginsberg MH (2005) Specification of the direction of adhesive signaling by the integrin beta cytoplasmic domain. J Biol Chem 280:29699-29707.
4. Barron-Casella EA, Nebbia G, Rogers OC, King KE, Kickler TS, and Casella JF (1999) Construction of a human platelet alloantigen-1a epitope(s) within murine glycoprotein IIIa: identification of residues critical to the conformation of the antibody binding site(s). Blood 93:2959-2967.
5. Bergmeier W, Schulte V, Brockhoff G, Bier U, Zirngibl H, and Nieswandt B (2002) Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry 48:80-86.
6. Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, Dutia M, Powell DW, Wissner A, Arndt K, and Weber JM et al. (2001) Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 44:822-833.
7. Bougie DW, Rasmussen M, Zhu J, and Aster RH (2012) Antibodies causing thrombocytopenia in patients treated with RGD-mimetic platelet inhibitors recognize ligand-specific conformers of αIIb/β3 integrin. Blood 119:6317-6325.
8. Calvete JJ (1994) Clues for understanding the structure and function of a prototypic human integrin: the platelet glycoprotein IIb/IIIa complex. Thromb Haemost 72:1-15.
9. Carneiro AM, Cook EH, Murphy DL, and Blakely RD (2008) Interactions between integrin alphaIIbbeta3 and the serotonin transporter regulate serotonin transport and platelet aggregation in mice and humans. J Clin Invest 118:1544-1552.
10. Chan PY, Kanner SB, Whitney G, and Aruffo A (1994) A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK. J Biol Chem 269:20567-20574.
11. Chen H, Kovar J, Sissons S, Cox K, Matter W, Chadwell F, Luan P, Vlahos CJ, Schutz-Geschwender A, and Olive DM (2005) A cell-based immunocytochemical assay for monitoring kinase signaling pathways and drug efficacy. Anal Biochem 338:136-142.
12. Cobb BS, Schaller MD, Leu TH, and Parsons JT (1994) Stable association of pp60src and pp59fyn with the focal adhesion-associated protein tyrosine kinase, pp125FAK. Mol Cell Biol 14:147-155.
13. Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, and Szczeklik A (2005) Antithrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin. Thromb Haemost 94:1300-1305.
14. 3 to bind fibrinogen continuously, but resulted in a severe bleeding syndrome and increased murine mortality. J Thromb Haemost 11:1163-1171.
15. Ghevaert C, Salsmann A, Watkins NA, Schaffner-Reckinger E, Rankin A, Garner SF, Stephens J, Smith GA, Debili N, and Vainchenker W et al. (2008) A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood 111:3407-3414.
16. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, and Boschelli F (2003) SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 63:375-381.
17. Goldschmidt-Clermont PJ, Cooke GE, Eaton GM, and Binkley PF (2000) PlA2, a variant of GPIIIa implicated in coronary thromboembolic complications. J Am Coll Cardiol 36:90-93.
18. Gong H, Shen B, Flevaris P, Chow C, Lam SC, Voyno-Yasenetskaya TA, Kozasa T, and Du X (2010) G protein subunit Galpha13 binds to integrin alphaIIbbeta3 and mediates integrin "outside-in" signaling. Science 327:340-343.
19. Goodall AH, Curzen N, Panesar M, Hurd C, Knight CJ, Ouwehand WH, and Fox KM (1999) Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PlA2, Zwb) positive platelets in patients with cardiovascular disease. Eur Heart J 20: 742-747.
20. Jallu V, Poulain P, Fuchs PF, Kaplan C, and de Brevern AG (2012) Modeling and molecular dynamics of HPA-1a and -1b polymorphisms: effects on the structure of the β3 subunit of the αIIbβ3 integrin. PLoS One 7:e47304.
21. Kim-Kaneyama JR, Miyauchi A, Lei XF, Arita S, Mino T, Takeda N, Kou K, Eto K, Yoshida T, and Miyazaki T et al. (2012) Identification of Hic-5 as a novel regulatory factor for integrin αIIbβ3 activation and platelet aggregation in mice. J Thromb Haemost 10:1867-1874.
22. Knowles JW, Wang H, Itakura H, Southwick A, Myers RM, Iribarren C, Fortmann SP, Go AS, Quertermous T, and Hlatky MA (2007) Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. Am Heart J 154:1052-1058.
23. Kunicki TJ and Nugent DJ (2002) The influence of platelet glycoprotein polymorphisms on receptor function and risk for thrombosis. Vox Sang 83 (Suppl 1): 85-90.
24. Lawson C and Schlaepfer DD (2012) Integrin adhesions: who's on first? What's on second? Connections between FAK and talin. Cell Adhes Migr 6:302-306.
25. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, and Kleiman NS (2007) Genetic polymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIa and response to aspirin and clopidogrel. Thromb Res 119:355-360.
26. Lippi G, Franchini M, and Targher G (2011) Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 8:502-512.
27. Michelson AD, Barnard MR, Krueger LA, Frelinger AL, 3rd, and Furman MI (2000a) Evaluation of platelet function by flow cytometry. Methods 21:259-270.
28. Michelson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, and Christie DJ et al. (2000b) Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101:1013-1018.
29. Mor-Cohen R, Rosenberg N, Peretz H, Landau M, Coller BS, Awidi A, and Seligsohn U (2007) Disulfide bond disruption by a beta 3-Cys549Arg mutation in six Jordanian families with Glanzmann thrombasthenia causes diminished production of constitutively active alpha IIb beta 3. Thromb Haemost 98:1257-1265.
30. Moser M, Nieswandt B, Ussar S, Pozgajova M, and Fässler R (2008) Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 14:325-330.
31. Motovska Z, Widimsky P, Kvasnicka J, Petr R, Bilkova D, Hajkova J, Marinov I, Simek S, and Kala P; PRAGUE-8 study investigators (2009). High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial. Blood Coagul Fibrinolysis 20:257-262.
32. Newman PJ, Derbes RS, and Aster RH (1989) The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 83:1778-1781.
33. Nieswandt B, Moser M, Pleines I, Varga-Szabo D, Monkley S, Critchley D, and Fässler R (2007) Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med 204:3113-3118.
34. Obergfell A, Eto K, Mocsai A, Buensuceso C, Moores SL, Brugge JS, Lowell CA, and Shattil SJ (2002) Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton. J Cell Biol 157: 265-275.
35. Osada M, Ohmori T, Yatomi Y, Satoh K, Hosogaya S, and Ozaki Y (2001) Involvement of Hic-5 in platelet activation: integrin alphaIIbbeta3-dependent tyrosine phosphorylation and association with proline-rich tyrosine kinase 2. Biochem J 355: 691-697.
36. Panetti TS (2002) Tyrosine phosphorylation of paxillin, FAK, and p130CAS: effects on cell spreading and migration. Front Biosci 7:d143-d150.
37. Phillips DR, Conley PB, Sinha U, and Andre P (2005) Therapeutic approaches in arterial thrombosis. J Thromb Haemost 3:1577-1589.
38. Quintás-Cardama A, Han X, Kantarjian H, and Cortes J (2009) Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 114:261-263.
39. Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, and Augustin M et al. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 23: 477-485.
40. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8:1227-1234.
41. Ruiz C, Liu CY, Sun QH, Sigaud-Fiks M, Fressinaud E, Muller JY, Nurden P, Nurden AT, Newman PJ, and Valentin N (2001) A point mutation in the cysteine-rich domain of glycoprotein (GP) IIIa results in the expression of a GPIIb-IIIa (alphaIIbbeta3) integrin receptor locked in a high-affinity state and a Glanzmann thrombasthenia-like phenotype. Blood 98:2432-2441.
42. Schaller MD, Hildebrand JD, Shannon JD, Fox JW, Vines RR, and Parsons JT (1994) Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol 14:1680-1688.
43. Schoenwaelder SM, Jackson SP, Yuan Y, Teasdale MS, Salem HH, and Mitchell CA (1994) Tyrosine kinases regulate the cytoskeletal attachment of integrin alpha IIb beta 3 (platelet glycoprotein IIb/IIIa) and the cellular retraction of fibrin polymers. J Biol Chem 269:32479-32487.
44. Serrels B and Frame MC (2012) FAK and talin: who is taking whom to the integrin engagement party? J Cell Biol 196:185-187.
45. Séverin S, Nash CA, Mori J, Zhao Y, Abram C, Lowell CA, Senis YA, and Watson SP (2012) Distinct and overlapping functional roles of Src family kinases in mouse platelets. J Thromb Haemost 10:1631-1645.
46. Smyth SS, Reis ED, Väänänen H, Zhang W, and Coller BS (2001) Variable protection of beta 3-integrin - deficient mice from thrombosis initiated by different mechanisms. Blood 98:1055-1062.
47. Tadokoro S, Shattil SJ, Eto K, Tai V, Liddington RC, de Pereda JM, Ginsberg MH, and Calderwood DA (2003) Talin binding to integrin beta tails: a final common step in integrin activation. Science 302:103-106.
48. Undas A, Brummel K, Musial J, Mann KG, and Szczeklik A (2001) Pl(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 104:2666-2672.
49. Varon D, and Spectre G (2009) Antiplatelet agents. Hematology Am Soc Hematol Educ Program 2009:267-272.
50. Vielreicher M, Harms G, Butt E, Walter U, and Obergfell A (2007) Dynamic interaction between Src and C-terminal Src kinase in integrin alphaIIbbeta3-mediated signaling to the cytoskeleton. J Biol Chem 282:33623-33631.
51. Vijayan KV, Huang TC, Liu Y, Bernardo A, Dong JF, Goldschmidt-Clermont PJ, Alevriadou BR, and Bray PF (2003a) Shear stress augments the enhanced adhesive phenotype of cells expressing the Pro33 isoform of integrin beta3. FEBS Lett 540: 41-46.
52. Vijayan KV, Liu Y, Dong JF, and Bray PF (2003b) Enhanced activation of mitogen-activated protein kinase and myosin light chain kinase by the Pro33 polymorphism of integrin beta 3. J Biol Chem 278:3860-3867.
53. Vijayan KV, Liu Y, Li TT, and Bray PF (2004) Protein phosphatase 1 associates with the integrin alphaIIb subunit and regulates signaling. J Biol Chem 279:33039-33042.
54. Vijayan KV, Liu Y, Sun W, Ito M, and Bray PF (2005) The Pro33 isoform of integrin beta3 enhances outside-in signaling in human platelets by regulating the activation of serine/threonine phosphatases. J Biol Chem 280:21756-21762.
55. Vinogradova O, Haas T, Plow EF, and Qin J (2000) A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. Proc Natl Acad Sci USA 97:1450-1455.
56. Wang R, McFarland JG, Kekomaki R, and Newman PJ (1993) Amino acid 489 is encoded by a mutational "hot spot" on the beta 3 integrin chain: the CA/TU human platelet alloantigen system. Blood 82:3386-3391.
57. Wang R and Newman PJ (1998) Adhesive and signaling properties of a naturally occurring allele of glycoprotein IIIa with an amino acid substitution within the ligand binding domain-the Pena/Penb platelet alloantigenic epitopes. Blood 92: 3260-3267.
58. Wegener KL, Partridge AW, Han J, Pickford AR, Liddington RC, Ginsberg MH, and Campbell ID (2007) Structural basis of integrin activation by talin. Cell 128: 171-182.
59. Xiao R, Xi XD, Chen Z, Chen SJ, and Meng G (2013) Structural framework of c-Src activation by integrin β3. Blood 121:700-706.
60. Xing Z, Chen HC, Nowlen JK, Taylor SJ, Shalloway D, and Guan JL (1994) Direct interaction of v-Src with the focal adhesion kinase mediated by the Src SH2 domain. Mol Biol Cell 5:413-421.
61. Xiong JP, Stehle T, Goodman SL, and Arnaout MA (2004) A novel adaptation of the integrin PSI domain revealed from its crystal structure. J Biol Chem 279: 40252-40254.
62. Yang J, Ma YQ, Page RC, Misra S, Plow EF, and Qin J (2009) Structure of an integrin alphaIIb beta3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation. Proc Natl Acad Sci USA 106:17729-17734.